IMUNON announced that its new DNA-based immunotherapy for advanced ovarian cancer has shown encouraging results in the ...

New data for darolutamide confirm safety and improved efficacy across subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC) by 40% and 70% respectively, compared to placebo ...

The FDA has approved Datroway® (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer. This innovative TROP2-directed antibody-drug ...

Ariceum Therapeutics announced that the US FDA has cleared its investigational new drug (IND) application to commence a Phase I/II clinical trial of its proprietary radiolabelled peptide, 225Ac-SSO110 ...